GlassScriptPhysician profile
Jameela Mitchell
NPI 1275044224
$4,392.01
in general payments reported to CMS, 2019-2025
11 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $331 · 2023: $1,261 · 2024: $869 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.09 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $897.17 | 2022-2025 | Caplyta |
| Indivior INC. | $547.32 | 2021-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $492.34 | 2023-2025 | Ingrezza |
| Braeburn INC. | $412.65 | 2023-2025 | Brixadi |
| Alkermes, INC. | $240.34 | 2023-2025 | Lybalvi, Vivitrol, Vivitrol |
| Lundbeck LLC | $130.64 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Orexo US, INC. | $121.54 | 2021-2025 | Zubsolv |
| Otsuka America Pharmaceutical, INC. | $83.24 | 2023-2025 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $82.86 | 2021-2022 | |
| Axsome Therapeutics, INC. | $16.82 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jameela Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.